Abstract Coronavirus disease 2019 (COVID-19) has emerged as a pandemic at the end of
2019 and continues to exert an unfavorable worldwide health impact on a large proportion …

Lung injury may persist during the recovery period of COVID-19 as shown through imaging,
six-minute walk, and lung function tests. The pathophysiological mechanisms leading to …

Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …

Infection by SARS-CoV-2 causing coronavirus disease 2019 (COVID-19) can be associated
with serious and life-threatening conditions, including acute respiratory distress syndrome …

A single center open label phase 2 randomised control trial (Clinical Trial Registry of India
No. CTRI/2020/05/025209) was done to assess clinical and immunological benefits of …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a viral agent that causes
Coronavirus disease 2019 (COVID-19), a disease that causes flu-like symptoms that, when …

The surface of all animal cells is coated with a layer of carbohydrates linked in various ways
to the outer side of the plasma membrane. These carbohydrates are mainly bound to …

Background The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and
a potential benefit of anticoagulation therapy has been documented for prevention of …

The COVID-19 pandemic severely affected healthcare systems and tested their
preparedness. To date, the length of hospital stay (LoHS) and its factors among COVID-19 …

In the lung, glycosaminoglycans (GAGs) are dispersed in the extracellular matrix (ECM)
occupying the interstitial space between the capillary endothelium and the alveolar …